NASDAQ:AZYO
Delisted
Aziyo Biologics Inc. Stock News
$1.49
+0 (+0%)
At Close: Dec 05, 2023
All You Need to Know About Aziyo Biologics, Inc. (AZYO) Rating Upgrade to Buy
05:00pm, Monday, 14'th Feb 2022 Zacks Investment Research
Aziyo Biologics, Inc. (AZYO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Has Aziyo Biologics, Inc. (AZYO) Outpaced Other Medical Stocks This Year?
02:40pm, Monday, 14'th Feb 2022 Zacks Investment Research
Here is how Aziyo Biologics, Inc. (AZYO) and Doximity (DOCS) have performed compared to their sector so far this year.
All You Need to Know About Aziyo Biologics, Inc. (AZYO) Rating Upgrade to Buy
01:10pm, Monday, 14'th Feb 2022
Aziyo Biologics, Inc. (AZYO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
PolarityTE (PTE) Gets FDA Nod to Begin Pivotal Ulcer Study
04:37pm, Wednesday, 19'th Jan 2022 Zacks Investment Research
PolarityTE (PTE) announces removal of clinical hold on a proposed pivotal study to evaluate its SkinTE for chronic cutaneous ulcers. PolarityTE plans to start enrollment in the next few months.
Wall Street Analysts See a 123% Upside in Aziyo Biologics, Inc. (AZYO): Can the Stock Really Move This High?
03:00pm, Tuesday, 11'th Jan 2022 Zacks Investment Research
The consensus price target hints at a 123.3% upside potential for Aziyo Biologics, Inc. (AZYO). While empirical research shows that this sought-after metric is hardly effective, an upward trend in ear
Aziyo Biologics to Present at the H.C. Wainwright Bioconnect Virtual Conference
09:01pm, Monday, 27'th Dec 2021 GlobeNewswire Inc.
SILVER SPRING, Md., Dec. 27, 2021 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO), a commercial-stage regenerative medicine company focused on creating the next generation of differentiated
Aziyo Biologics to Present at the H.C. Wainwright Bioconnect Virtual Conference
04:01pm, Monday, 27'th Dec 2021
SILVER SPRING, Md., Dec. 27, 2021 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO), a commercial-stage regenerative medicine company focused on creating the next generation of differentiated p
Truist Securiti Analysts Lift Earnings Estimates for Aziyo Biologics, Inc. (NASDAQ:AZYO)
06:12am, Friday, 24'th Dec 2021 Transcript Daily
Aziyo Biologics, Inc. (NASDAQ:AZYO) Analysts at Truist Securiti boosted their FY2021 EPS estimates for Aziyo Biologics in a report released on Tuesday, December 21st. Truist Securiti analyst D. Rescott now expects that the company will post earnings of ($1.83) per share for the year, up from their previous estimate of ($1.87). Truist Securiti also []
Aziyo Biologics (NASDAQ:AZYO) Rating Increased to Hold at Zacks Investment Research
06:20am, Sunday, 19'th Dec 2021 Transcript Daily
Aziyo Biologics (NASDAQ:AZYO) was upgraded by Zacks Investment Research from a sell rating to a hold rating in a research note issued to investors on Friday, Zacks.com reports. According to Zacks, Aziyo Biologics Inc.is a regenerative medicine company. It focuses on the development of regenerative medical products to address the implantable electronic device/cardiovascular, orthopedic/spinal repair, []
58 Biggest Movers From Yesterday
10:15am, Tuesday, 14'th Dec 2021 Benzinga
Gainers Arena Pharmaceuticals, Inc. (NASDAQ: ARNA ) shares jumped 80.4% to close at $90.08 on Monday. Pfizer agreed to acquire Arena Pharmaceuticals for $100 per share in an all-cash transaction. Foghorn Therapeutics Inc. (NASDAQ: FHTX ) shares jumped 55% to close at $18.58. Loxo Oncology, an R&D group of Eli Lilly And Co (NYSE: LLY ), and Foghorn Therapeutics collaborated to create oncology medicines by applying Foghorn''s Gene Traffic Control platform. BELLUS Health Inc. (NASDAQ: BLU ) gained 48.2% to settle at $8.30 after the company announced topline data its Phase 2b SOOTHE trial of BLU-5937 in Refractory Chronic Cough. Petros Pharmaceuticals, Inc. (NASDAQ: PTPI ) surged 47.4% to close at $3.98 after gaining more than 14% on Friday. Energy Focus, Inc. (NASDAQ: EFOI ) gained 36.2% to close at $4.70. East Stone Acquisition Corporation (NASDAQ: ESSC ) jumped 31.4% to close at $18.40 after gaining over 8% on Friday. Puxin Limited (NYSE: NEW ) climbed 27.1% to settle at $0.41 after tumbling over 10% on Friday.
Analyzing Denali Therapeutics (NASDAQ:DNLI) and Aziyo Biologics (NASDAQ:AZYO)
02:20pm, Friday, 10'th Dec 2021 Dakota Financial News
Denali Therapeutics (NASDAQ:DNLI) and Aziyo Biologics (NASDAQ:AZYO) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, valuation, dividends, analyst recommendations, profitability, institutional ownership and earnings. Analyst Ratings This is a summary of recent ratings and recommmendations for Denali Therapeutics and Aziyo []
Perkins Capital Management Inc. Purchases 74,000 Shares of Aziyo Biologics, Inc. (NASDAQ:AZYO)
04:04pm, Thursday, 09'th Dec 2021 Dakota Financial News
Perkins Capital Management Inc. boosted its position in Aziyo Biologics, Inc. (NASDAQ:AZYO) by 47.9% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 228,425 shares of the companys stock after acquiring an additional 74,000 shares during the quarter. Perkins Capital []
Aziyo Biologics Announces Closing of $14.0 Million Private Placement
10:31pm, Wednesday, 08'th Dec 2021 GlobeNewswire Inc.
SILVER SPRING, Md., Dec. 08, 2021 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (the “Company”), a commercial-stage regenerative medicine company focused on creating the next generation of different
Aziyo Biologics Announces Closing of $14.0 Million Private Placement
10:31pm, Wednesday, 08'th Dec 2021 Intrado Digital Media
SILVER SPRING, Md., Dec. 08, 2021 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (the Company), a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, today announced the closing of the previously announced private investment in public equity (PIPE) financing. The Company received aggregate gross proceeds of approximately $14.0 million, before deducting offering expenses. The PIPE financing was led by a fund affiliated with Birchview Capital, with participation from existing investors including funds affiliated with Deerfield Management Company and HighCape Capital.
Aziyo Biologics Announces $14.0 Million Private Placement
11:59am, Monday, 06'th Dec 2021 ForexTV
SILVER SPRING, Md., Dec. 06, 2021 (GLOBE NEWSWIRE) Aziyo Biologics, Inc. (the Company) today announced that it has entered into a definitive agreement to sell securities in a private placement that is expected to result in gross proceeds to the Company of approximately $14.0 million, before deducting offering expenses. Certain accredited investors have agreed The post Aziyo Biologics Announces $14.0 Million Private Placement appeared first on ForexTV .